WANY
PRVB

Wealthspire Advisors (New York)’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Wealthspire Advisors (New York)’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,200
Closed -$238K – 600
2021
Q2 		$238K Hold
28,200
– – 0.01% 331
2021
Q1 		$296K Sell
28,200
-15,000
-35% -$211K 0.01% 555
2020
Q4 		$732K Buy
+43,200
New +$648K 0.02% 249
2020
Q2 		– Sell
-80,000
Closed -$736K – 556
2020
Q1 		$736K Buy
+80,000
New +$1.03M 0.03% 240

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Wealthspire Advisors (New York)'s PRVB Position: Q3 2021 in Review

Wealthspire Advisors (New York) sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2021, closing a stake of 28,200 shares — an estimated $238K sold.

Wealthspire Advisors (New York) first reported a position in PRVB in Q1 2020 and held it in 4 quarters. The position peaked at $736K in Q1 2020. 115 funds tracked by Wall St. Rank hold PRVB as of Q3 2021.

  • Wealthspire Advisors (New York) reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 28,200 Provention Bio, Inc. Common Stock shares in Q3 2021, an estimated $238K.
  • Wealthspire Advisors (New York) first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • Wealthspire Advisors (New York)'s Provention Bio, Inc. Common Stock position peaked at $736K in Q1 2020.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2021.

Based on Wealthspire Advisors (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.